2-pyrrolino-dox has been researched along with Experimental Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Engel, JB; Halmos, G; Hammann, B; Keller, G; Nagy, A; Schally, AV | 1 |
| Halmos, G; Nagy, A; Plonowski, A; Schally, AV; Sun, B | 1 |
2 other study(ies) available for 2-pyrrolino-dox and Experimental Neoplasms
| Article | Year |
|---|---|
Growth inhibition of experimental non-Hodgkin's lymphomas with the targeted cytotoxic somatostatin analogue AN-238.
Topics: Animals; Antineoplastic Agents; Body Weight; Doxorubicin; Humans; Kinetics; Leukocytes; Lymphoma, Non-Hodgkin; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Peptides; Pyrroles; Receptors, Somatostatin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Somatostatin; Time Factors | 2005 |
Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238.
Topics: Animals; Antibiotics, Antineoplastic; Cell Division; Cytotoxins; Doxorubicin; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Octreotide; Prostatic Neoplasms; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Treatment Outcome; Tumor Cells, Cultured | 2002 |